Cite
1250P Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017).
MLA
Su, L., et al. “1250P Camrelizumab plus Apatinib Combined with POF in Patients with Untreated Advanced Gastric Cancer (UAGC): A Single-Center, Open-Label, Single-Arm, Phase II Trial (SYLT-017).” Annals of Oncology, vol. 33, Sept. 2022, pp. S1119–20. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.1368.
APA
Su, L., Zhao, S., Lin, P., Yin, Y., & Lin, R. (2022). 1250P Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017). Annals of Oncology, 33, S1119–S1120. https://doi.org/10.1016/j.annonc.2022.07.1368
Chicago
Su, L., S. Zhao, P. Lin, Y. Yin, and R. Lin. 2022. “1250P Camrelizumab plus Apatinib Combined with POF in Patients with Untreated Advanced Gastric Cancer (UAGC): A Single-Center, Open-Label, Single-Arm, Phase II Trial (SYLT-017).” Annals of Oncology 33 (September): S1119–20. doi:10.1016/j.annonc.2022.07.1368.